Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas - Wikidata - wikimedia - TriplyDB

Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas

Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas

http://www.wikidata.org/entity/Q26991890

about

FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies Second-generation inhibitors of Bruton tyrosine kinase Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation Switching immune signals on and off.Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants Bruton's tyrosine kinase promotes persistence of mature anti-insulin B cells.Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia.Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.Hairy cell leukemia - immunotargets and therapies Molecular abnormalities of the B cell in systemic lupus erythematosus are candidates for functional inhibition treatments.Control of macrophage 3D migration: a therapeutic challenge to limit tissue infiltration.Novel therapeutic options for relapsed hairy cell leukemia.X-linked agammaglobulinemia associated with B-precursor acute lymphoblastic leukemia.Molecular deregulation of signaling in lymphoid tumors.Ofatumumab in the treatment of non-Hodgkin's lymphomas.A general approach for the development of fluorogenic probes suitable for no-wash imaging of kinases in live cells.Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.Transformed follicular lymphoma.Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma.Molecular modeling studies on series of Btk inhibitors using docking, structure-based 3D-QSAR and molecular dynamics simulation: a combined approach.

P2860

Q24304887-D8081435-BE40-403D-A3CD-87ADBBEDE0A8 Q26995113-E27C99E1-97CB-47C4-8F7E-DE5E602CA84D Q28067817-8E553043-89B8-4CEC-ABCC-3A90E67AF121 Q28076118-2611B63F-16FB-4AF8-9624-9B3466297350 Q28552585-41F53B68-4AFD-494D-ABC7-E420AB67E556 Q30373352-37159B6A-9E93-4E2B-953D-AA60A4894B84 Q33653945-377E58CF-F7F3-4EE7-AC83-8591CBD1C144 Q33852815-52E226E1-2F62-4A8F-8906-2B12D946D299 Q33920352-1834DB43-101B-4200-ACEA-6CB44E439FB0 Q36533710-F5370A55-C8AE-4B81-AC85-04431B1DC019 Q37031666-681CE37B-C317-44A3-8ABA-96FE7F6577B5 Q38192725-E04AE033-F2DE-4540-8D32-F0C2226588E5 Q38260573-C3E81C5C-2268-40D0-B2F4-9C3D7E418E49 Q38308974-9104A72B-216C-44D2-96C6-4020FA0C98EA Q38319601-86E8D3A0-32AE-4EA1-BC24-87A3B95CF3B6 Q38424403-CDFFF4B7-824A-4461-BEC6-F22B70DD893C Q38516077-733FD1D3-328B-4701-85B2-1EB787DC91A9 Q38944958-203BCE9C-E557-4B84-A2BA-DCCCDDAC4802 Q38989496-CBEE606F-0E86-4D71-8509-48FD56B3EF4F Q42318090-1D6F4042-B296-4F1F-806F-5A2E1C00FDBB Q47771789-A724CFC8-4D18-4DB1-B85F-50D0B02465A2 Q47932240-71649C38-9996-4631-9242-386D23739229 Q53089985-848794D0-0B0F-4C1E-98FE-B1D8E0A2F883 Q53186853-D9822EC5-72FE-4C1D-AE49-C8D68278552F Q55033575-DE6ED155-585F-4851-80C1-09A9127F2E9A

P2860

Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas

http://www.wikidata.org/entity/Q26991890

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Bruton tyrosine kinase inhibit ...... treatment for B cell lymphomas

@ast

Bruton tyrosine kinase inhibit ...... treatment for B cell lymphomas

@en

Bruton tyrosine kinase inhibit ...... treatment for B cell lymphomas

@nl

type

label

Bruton tyrosine kinase inhibit ...... treatment for B cell lymphomas

@ast

Bruton tyrosine kinase inhibit ...... treatment for B cell lymphomas

@en

Bruton tyrosine kinase inhibit ...... treatment for B cell lymphomas

@nl

prefLabel

Bruton tyrosine kinase inhibit ...... treatment for B cell lymphomas

@ast

Bruton tyrosine kinase inhibit ...... treatment for B cell lymphomas

@en

Bruton tyrosine kinase inhibit ...... treatment for B cell lymphomas

@nl

P1433

Q26991890-2EE1A956-52EF-49D6-B8B4-D598D69EF891

P1476

Q26991890-1D7A0A0F-A891-46D6-819E-82225491AFED

P2093

Q26991890-155FEF63-E692-406D-9DE8-B1104A4537F2

Q26991890-75C132F7-E0D8-409E-821C-5C910FA4B9BB

P2860

Q26991890-02789A2C-38DC-4EE3-BB09-E9077B7CBF5D

Q26991890-041E6D96-513E-4F70-AA0A-E052BEFD4071

Q26991890-0BEE84ED-584D-4E78-B1C8-810E0843F19C

Q26991890-0D29D71E-9E92-4F5D-BF0A-23E65FD98477

Q26991890-0DBECFD8-B473-493D-AFB2-3377AF7B14A7

Q26991890-15CD5C2D-2764-486C-B44F-91B073FAFA2F

Q26991890-19FC97E5-13BE-421D-A85A-E0CFEC48C5B2

Q26991890-1DF0BF89-3AC8-4D83-B64E-67CAB44A4C78

Q26991890-21F7DE90-C0CD-4191-AEF3-88016005513C

Q26991890-424E1A54-6B48-4013-B308-B6269C030F1A

P304

Q26991890-CA53999F-38EC-4C00-9409-9B85836A91BF

P31

Q26991890-C7AD082D-0F29-4A72-942A-10E1102127DC

P3181

Q26991890-782273DC-08E2-4E20-A962-E878C370F288

P356

Q26991890-D8316602-BD5C-4365-96F3-14B8478AB0E0

P407

Q26991890-D8AA1A69-4F5E-4D99-AE16-3CC48B6201A2

P433

Q26991890-052D46AB-6F02-455F-BDDA-48CAC1EC905F

P478

Q26991890-717F19A6-91CD-4704-B6A3-D34122AF397F

P577

Q26991890-EEA150CD-DE36-456F-AFF6-F2DBC6A674A9

P698

Q26991890-D7E09E02-E31F-4AD4-8780-4D32C6DB3AFF

P921

Q26991890-68C7A855-25E5-435C-A3FC-0C6717C62C9A

P932

Q26991890-1DC801B1-4A59-4849-ADAB-06D9597E7EBE

P3181

P356

P1433

British Journal of Haematology

P1476

Bruton tyrosine kinase inhibit ...... treatment for B cell lymphomas

@en

P2093

Amin Aalipour

http://www.w3.org/2001/XMLSchema#string

Ranjana H. Advani

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

Oncogenically active MYD88 mutations in human lymphoma

Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

P304

436-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3698347

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/BJH.12573

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

163

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24111579

http://www.w3.org/2001/XMLSchema#string

P921

P932

4444436

http://www.w3.org/2001/XMLSchema#string